These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492 [TBL] [Abstract][Full Text] [Related]
4. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Carta M; Carlsson T; Muñoz A; Kirik D; Björklund A Prog Brain Res; 2008; 172():465-78. PubMed ID: 18772046 [TBL] [Abstract][Full Text] [Related]
5. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677 [TBL] [Abstract][Full Text] [Related]
6. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM Pharmacol Rev; 2013 Jan; 65(1):171-222. PubMed ID: 23319549 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244 [TBL] [Abstract][Full Text] [Related]
10. Opioids and motor complications in Parkinson's disease. Samadi P; Bédard PJ; Rouillard C Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075 [TBL] [Abstract][Full Text] [Related]
11. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364 [TBL] [Abstract][Full Text] [Related]
12. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Carta M; Carlsson T; Kirik D; Björklund A Brain; 2007 Jul; 130(Pt 7):1819-33. PubMed ID: 17452372 [TBL] [Abstract][Full Text] [Related]
13. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628 [TBL] [Abstract][Full Text] [Related]
14. Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in L-dopa-induced dyskinesia. Guigoni C; Bezard E Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S64-7. PubMed ID: 20083011 [TBL] [Abstract][Full Text] [Related]
15. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978 [TBL] [Abstract][Full Text] [Related]
16. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease. Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008 [TBL] [Abstract][Full Text] [Related]
17. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)]. Damier P; Tremblay L; Féger J; Hirsch EC Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093 [TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy. Fox SH; Chuang R; Brotchie JM Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047 [TBL] [Abstract][Full Text] [Related]
19. What has been learnt from study of dopamine receptors in Parkinson's disease? Hurley MJ; Jenner P Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973 [TBL] [Abstract][Full Text] [Related]